Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab

뉴스 본문을 불러오고 있어요.

Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab | 웨이프 WAPE

Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab

기사 요약

관련 종목

댓글 —